In addition, the combination therapy increased IFN-γ production and proliferation of TIM-3+CD8+ T cells from PD-1-resistant mice, as well as decreased the expression of some tumor-promoting cytokines, such as IL-6 and progranulin 91. The gene discussed is HAVCR2; the disease is neoplasm.